{
      "Rank": 153,
      "Acronym": [
            "CRATUS"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [
            "Yes"
      ],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
            "Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
            "Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
            "Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.",
            "Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.",
            "Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.",
            "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval."
      ],
      "ArmGroupInterventionName": [
            "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
            "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
            "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
            "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
            "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
            "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
            "Biological: Placebo",
            "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
            "Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)"
      ],
      "ArmGroupLabel": [
            "Pilot phase - Group 1",
            "Pilot Phase - Group 2",
            "Pilot Phase - Group 3",
            "Randomized Phase - Group A",
            "Randomized phase - Group B",
            "Randomized Phase - Group C",
            "Addendum B - Antibiotic free cell Group"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "Experimental",
            "Experimental",
            "Experimental",
            "Experimental",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "Female",
            "Male",
            "Hispanic or Latino",
            "Not Hispanic or Latino",
            "Unknown or Not Reported",
            "American Indian or Alaska Native",
            "Asian",
            "Native Hawaiian or Other Pacific Islander",
            "Black or African American",
            "White",
            "More than one race",
            "Unknown or Not Reported"
      ],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02065245"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007"
      ],
      "BaselineDenomCountValue": [
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20",
            "65"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPlacebo: Placebo administered by peripheral intravenous infusion.",
            "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPenicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion.",
            "Total of all reporting groups"
      ],
      "BaselineGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007"
      ],
      "BaselineGroupTitle": [
            "Pilot Phase - Group 1",
            "Pilot Phase - Group 2",
            "Pilot Phase - Group 3",
            "Randomized Phase - Group A",
            "Randomized Phase - Group B",
            "Randomized Phase - Group C",
            "Addendum B - Antibiotic Free Cell Group",
            "Total"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [
            "Standard Deviation"
      ],
      "BaselineMeasureParamType": [
            "Mean",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants"
      ],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [
            "Age, Continuous",
            "Sex: Female, Male",
            "Ethnicity (NIH/OMB)",
            "Race (NIH/OMB)"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "years",
            "Participants",
            "Participants",
            "Participants"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007",
            "BG000",
            "BG001",
            "BG002",
            "BG003",
            "BG004",
            "BG005",
            "BG006",
            "BG007"
      ],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [
            "5.167",
            "4.868",
            "4.024",
            "7.23",
            "8.293",
            "6.75",
            "8.896",
            "7.443"
      ],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [
            "78.8",
            "75.8",
            "79.2",
            "74.6",
            "75.9",
            "74.7",
            "72.75",
            "75.015",
            "3",
            "0",
            "2",
            "4",
            "4",
            "4",
            "7",
            "24",
            "2",
            "5",
            "3",
            "6",
            "6",
            "6",
            "13",
            "41",
            "0",
            "0",
            "0",
            "1",
            "1",
            "2",
            "1",
            "5",
            "5",
            "5",
            "5",
            "9",
            "9",
            "8",
            "19",
            "60",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "5",
            "5",
            "5",
            "10",
            "9",
            "10",
            "20",
            "64",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to look at the safety of treatment with stem cells in patients with Frailty."
      ],
      "BriefTitle": [
            "AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "INDUSTRY"
      ],
      "CollaboratorName": [
            "The Emmes Company, LLC"
      ],
      "CompletionDate": [
            "October 2, 2020"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Frailty"
      ],
      "ConditionAncestorId": [
            "D000010335"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Frailty"
      ],
      "ConditionBrowseLeafId": [
            "M1175"
      ],
      "ConditionBrowseLeafName": [
            "Frailty"
      ],
      "ConditionBrowseLeafRelevance": [
            "high"
      ],
      "ConditionMeshId": [
            "D000073496"
      ],
      "ConditionMeshTerm": [
            "Frailty"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Double"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nProvide written informed consent.\nSubjects age greater than or equal to 60 and less than or equal to 95 years at the time of signing the Informed Consent Form.\nShow signs of frailty apart from a concomitant condition as assessed by the Investigator with a frailty score of 4 to 7 using the Clinical Frailty Scale\nFemale subjects with an Follicle-stimulating hormone (FSH) equal to or > 25.8 milli-international units (mIU) /mL (milliliter), if not currently on hormone replacement therapy.\n\nExclusion Criteria:\n\nScore of less than or equal to 24 on the Mini Mental State Examination (MMSE)\nInability to perform any of the assessments required for endpoint analysis (report safety or tolerability concerns, perform pulmonary function tests, undergo blood draws, read and respond to questionnaires.\nActive listing (or expected future listing) for transplant of any organ.\nClinically important abnormal screening laboratory values, including but not limited to: hemoglobin <8 g/dl, white blood cell count <3000/mm3, platelets<80,000/mm3, international normalized ratio (INR) > 1.5 not due to a reversible cause (i.e. Coumadin), aspartate transaminase, alanine transaminase, or alkaline phosphatase > 3 times upper limit of normal, total bilirubin > 1.5 mg/dl.\nSerious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study. Including, but not limited to: HIV, advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, or cardiac revascularization within the last six months, or severe obstructive ventilatory defect.\nAny other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.\nBe an organ transplant recipient.\nHave a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma if recurrence occurs.\nHave a non-pulmonary condition that limits lifespan to < 1 year.\nHave a history of drug or alcohol abuse within the past 24 months.\nBe serum positive for HIV, hepatitis B Surface Antigen (BsAg) or Viremic hepatitis C.\nBe currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.\nBe a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.\nHave hypersensitivity to dimethyl sulfoxide (DMSO)"
      ],
      "EnrollmentCount": [
            "65"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1"
      ],
      "EventGroupDeathsNumAtRisk": [
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20"
      ],
      "EventGroupDescription": [
            "Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPlacebo: Placebo administered by peripheral intravenous infusion.",
            "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPenicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion."
      ],
      "EventGroupId": [
            "EG000",
            "EG001",
            "EG002",
            "EG003",
            "EG004",
            "EG005",
            "EG006"
      ],
      "EventGroupOtherNumAffected": [
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
      ],
      "EventGroupOtherNumAtRisk": [
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20"
      ],
      "EventGroupSeriousNumAffected": [
            "0",
            "1",
            "1",
            "0",
            "2",
            "0",
            "1"
      ],
      "EventGroupSeriousNumAtRisk": [
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20"
      ],
      "EventGroupTitle": [
            "Pilot Phase - Group 1",
            "Pilot Phase - Group 2",
            "Pilot Phase - Group 3",
            "Randomized Phase - Group A",
            "Randomized Phase - Group B",
            "Randomized Phase - Group C",
            "Addendum B - Antibiotic Free Cell Group"
      ],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [
            "0"
      ],
      "EventsTimeFrame": [
            "Up to 6 years"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006"
      ],
      "FlowAchievementNumSubjects": [
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20",
            "5",
            "5",
            "4",
            "10",
            "9",
            "10",
            "19",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "5",
            "5",
            "2",
            "0",
            "0",
            "6",
            "12",
            "5",
            "5",
            "2",
            "0",
            "0",
            "6",
            "11",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "3",
            "5",
            "1",
            "0",
            "0",
            "0",
            "0",
            "2",
            "4",
            "1",
            "0",
            "0",
            "0",
            "0",
            "1",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "2",
            "1",
            "0",
            "0",
            "0",
            "0",
            "1",
            "2",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [
            "Lost to Follow-up",
            "Death",
            "Death",
            "Lost to Follow-up"
      ],
      "FlowGroupDescription": [
            "Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPlacebo: Placebo administered by peripheral intravenous infusion.",
            "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPenicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion."
      ],
      "FlowGroupId": [
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006"
      ],
      "FlowGroupTitle": [
            "Pilot Phase - Group 1",
            "Pilot Phase - Group 2",
            "Pilot Phase - Group 3",
            "Randomized Phase - Group A",
            "Randomized Phase - Group B",
            "Randomized Phase - Group C",
            "Addendum B - Antibiotic Free Cell Group"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED",
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED",
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED",
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Infusion 1",
            "Infusion 2",
            "Infusion 3",
            "Infusion 4"
      ],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006",
            "FG000",
            "FG001",
            "FG002",
            "FG003",
            "FG004",
            "FG005",
            "FG006"
      ],
      "FlowReasonNumSubjects": [
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "1",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0"
      ],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000900",
            "D000000890",
            "D000011500",
            "D000004791",
            "D000045504"
      ],
      "InterventionAncestorTerm": [
            "Anti-Bacterial Agents",
            "Anti-Infective Agents",
            "Protein Synthesis Inhibitors",
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action"
      ],
      "InterventionArmGroupLabel": [
            "Addendum B - Antibiotic free cell Group",
            "Pilot Phase - Group 2",
            "Pilot Phase - Group 3",
            "Pilot phase - Group 1",
            "Randomized Phase - Group A",
            "Randomized Phase - Group C",
            "Randomized phase - Group B",
            "Randomized Phase - Group C",
            "Addendum B - Antibiotic free cell Group"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Hip Replacement",
            "Surface electromyography"
      ],
      "InterventionBrowseLeafId": [
            "M3374",
            "M12469",
            "M3376",
            "M15249",
            "M3366"
      ],
      "InterventionBrowseLeafName": [
            "Anti-Bacterial Agents",
            "Penicillins",
            "Antibiotics, Antitubercular",
            "Streptomycin",
            "Anti-Infective Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "high",
            "low",
            "high",
            "low"
      ],
      "InterventionDescription": [
            "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Placebo administered by peripheral intravenous infusion.",
            "Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion."
      ],
      "InterventionMeshId": [
            "D000010406",
            "D000013307"
      ],
      "InterventionMeshTerm": [
            "Penicillins",
            "Streptomycin"
      ],
      "InterventionName": [
            "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
            "Placebo",
            "Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Biological",
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Aging Frailty",
            "Frailty",
            "Cardiovascular",
            "Stem Cells"
      ],
      "LargeDocDate": [
            "March 19, 2021"
      ],
      "LargeDocFilename": [
            "Prot_SAP_000.pdf"
      ],
      "LargeDocHasICF": [
            "No"
      ],
      "LargeDocHasProtocol": [
            "Yes"
      ],
      "LargeDocHasSAP": [
            "Yes"
      ],
      "LargeDocLabel": [
            "Study Protocol and Statistical Analysis Plan"
      ],
      "LargeDocTypeAbbrev": [
            "Prot_SAP"
      ],
      "LargeDocUploadDate": [
            "03/25/2021 10:04"
      ],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "July 14, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "July 13, 2021"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Longeveron Inc."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Miami"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "ISCI/University of Miami Miller School of Medicine"
      ],
      "LocationState": [
            "Florida"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "33136"
      ],
      "MaximumAge": [
            "95 Years"
      ],
      "MinimumAge": [
            "60 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Longeveron Inc."
      ],
      "OrgStudyId": [
            "20130646"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG002",
            "OG003",
            "OG004",
            "OG005",
            "OG006",
            "OG000",
            "OG001",
            "OG002",
            "OG003",
            "OG004",
            "OG005",
            "OG006",
            "OG000",
            "OG001",
            "OG002",
            "OG003",
            "OG004",
            "OG005",
            "OG006",
            "OG000",
            "OG001",
            "OG002",
            "OG003",
            "OG004",
            "OG005",
            "OG006"
      ],
      "OutcomeClassDenomCountValue": [
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20",
            "5",
            "5",
            "2",
            "0",
            "0",
            "6",
            "12",
            "3",
            "5",
            "1",
            "0",
            "0",
            "0",
            "0",
            "1",
            "2",
            "1",
            "0",
            "0",
            "0",
            "0"
      ],
      "OutcomeClassDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeClassTitle": [
            "Infusion #1",
            "Infusion #2",
            "Infusion #3",
            "infusion #4"
      ],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG002",
            "OG003",
            "OG004",
            "OG005",
            "OG006"
      ],
      "OutcomeDenomCountValue": [
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20"
      ],
      "OutcomeDenomUnits": [
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion",
            "Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPlacebo: Placebo administered by peripheral intravenous infusion.",
            "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.\n\nAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion\n\nPenicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) administered by peripheral intravenous infusion."
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG001",
            "OG002",
            "OG003",
            "OG004",
            "OG005",
            "OG006"
      ],
      "OutcomeGroupTitle": [
            "Pilot Phase - Group 1",
            "Pilot Phase - Group 2",
            "Pilot Phase - Group 3",
            "Randomized Phase - Group A",
            "Randomized Phase - Group B",
            "Randomized Phase - Group C",
            "Addendum B - Antibiotic Free Cell Group"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeMeasureDescription": [
            "Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.\n\nSerum chemistry: chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, calcium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (fractionate if total >1.5 times normal), alkaline phosphatase, albumin,\nHematology (Complete blood count): hemoglobin, hematocrit, platelets, white blood cells (WBC), WBC differential",
            "Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire measures duration of exercise-related activities (hours/week). The Duration variable can range from 0 - 399.75 hours per week. Higher scores indicate more activity.",
            "4-meter gait speed test measures the time (in seconds) taken to walk a distance of 4 meters. The total score has a range of 1 point - 4 points with the higher score indicating faster walk speed.",
            "Standard Physical Performance Battery (SPPB) Assessment has total score ranging from 0-4 with the higher score indicating better balance.",
            "Change in weight as measured in kilograms (kg).",
            "Hand grip strength as assessed by a dynamometer. Grip strength is recorded (in mmHg) three times for each hand. The average reading is reported for each hand.",
            "Multi-dimensional Fatigue Inventory (MFI) Questionnaire contains 20 questions with a 5-point scale. The MFI has total score ranging from 20-100 with the higher score indicating less fatigue.",
            "Investigating Choice Experiences for the Preferences of Older People (ICEpop) Capability measure for Older people (ICECAP) questionnaire has total score ranging from 5-20 with the higher score indicating greater quality of life.",
            "Short Form (SF)-36 Questionnaire has consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. Lower scores indicate the more disability, and higher scores indicate less disability.",
            "EuroQoL (EQ)- 5 Dimension (5D)- 3 levels (3L) Questionnaire has total score ranging from 0-10 for the 5 dimensions. Higher scores indicate better Quality of Life.",
            "EuroQoL - 5 Dimension - 3 levels (EQ-5D-3L) Overall health status question has a range of 0-100. Higher scores indicate better Quality of Life.",
            "University of Pennsylvania Smell Identification Test (UPSIT) smell test booklet has a total score ranging from 0-40 with higher scores indicating better olfaction.",
            "Any reported death from any cause.",
            "Change in dobutamine stress echocardiogram induced ejection fraction",
            "Change in inflammatory markers including C-Reactive Protein (CRP) and Fibrinogen serum samples as measured in mg/L.",
            "Change in inflammatory markers including Interleukin (IL)-6 and Tumor Necrosis Factor (TNF) Alpha from serum samples as measured in pg/mL.",
            "Change in inflammatory marker D-Dimer from serum samples as measured in mg/dL."
      ],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [
            "Number"
      ],
      "OutcomeMeasurePopulationDescription": [
            "Participants were allowed to opt-in to receive additional infusion based on cohort"
      ],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted",
            "Not Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "One Month post infusion",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "Up to 12 months.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit."
      ],
      "OutcomeMeasureTitle": [
            "Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)",
            "Change in Frailty as Assessed by CHAMPS Questionnaire",
            "Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test",
            "Change in Slowing of Mobility as Measured by SPPB",
            "Change in Weight",
            "Change in Diminished Hand Grip Strength",
            "Change in Exhaustion as Measured by the MFI Questionnaire",
            "Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire",
            "Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire",
            "Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire",
            "Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale.",
            "Change in Sense of Smell as Measured by UPSIT",
            "Death",
            "Change in Ejection Fraction (EF)",
            "Change in Inflammatory Markers Levels",
            "Change in Inflammatory Markers",
            "Change in Inflammatory Marker D-dimer Levels"
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "Incidents"
      ],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG001",
            "OG002",
            "OG003",
            "OG004",
            "OG005",
            "OG006",
            "OG000",
            "OG001",
            "OG002",
            "OG005",
            "OG006",
            "OG000",
            "OG001",
            "OG002",
            "OG000",
            "OG001",
            "OG002"
      ],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0"
      ],
      "OverallOfficialAffiliation": [
            "ISCI / University of Miami Miller School of Medicine"
      ],
      "OverallOfficialName": [
            "Joshua M Hare, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [
            "JHare@med.miami.edu"
      ],
      "PointOfContactOrganization": [
            "University of Miami, Miller School of Medicine - Interdisciplinary Stem Cell Institute (ISCI)"
      ],
      "PointOfContactPhone": [
            "305-243-5579"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Joshua M Hare, MD"
      ],
      "PrimaryCompletionDate": [
            "October 2, 2019"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.\n\nSerum chemistry: chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, calcium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (fractionate if total >1.5 times normal), alkaline phosphatase, albumin,\nHematology (Complete blood count): hemoglobin, hematocrit, platelets, white blood cells (WBC), WBC differential"
      ],
      "PrimaryOutcomeMeasure": [
            "Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "One Month post infusion"
      ],
      "ReferenceCitation": [
            "Golpanian S, DiFede DL, Pujol MV, Lowery MH, Levis-Dusseau S, Goldstein BJ, Schulman IH, Longsomboon B, Wolf A, Khan A, Heldman AW, Goldschmidt-Clermont PJ, Hare JM. Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty. Oncotarget. 2016 Mar 15;7(11):11899-912. doi: 10.18632/oncotarget.7727.",
            "Tompkins BA, DiFede DL, Khan A, Landin AM, Schulman IH, Pujol MV, Heldman AW, Miki R, Goldschmidt-Clermont PJ, Goldstein BJ, Mushtaq M, Levis-Dusseau S, Byrnes JJ, Lowery M, Natsumeda M, Delgado C, Saltzman R, Vidro-Casiano M, Da Fonseca M, Golpanian S, Premer C, Medina A, Valasaki K, Florea V, Anderson E, El-Khorazaty J, Mendizabal A, Green G, Oliva AA, Hare JM. Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1513-1522. doi: 10.1093/gerona/glx137.",
            "Golpanian S, DiFede DL, Khan A, Schulman IH, Landin AM, Tompkins BA, Heldman AW, Miki R, Goldstein BJ, Mushtaq M, Levis-Dusseau S, Byrnes JJ, Lowery M, Natsumeda M, Delgado C, Saltzman R, Vidro-Casiano M, Pujol MV, Da Fonseca M, Oliva AA Jr, Green G, Premer C, Medina A, Valasaki K, Florea V, Anderson E, El-Khorazaty J, Mendizabal A, Goldschmidt-Clermont PJ, Hare JM. Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty. J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1505-1512. doi: 10.1093/gerona/glx056."
      ],
      "ReferencePMID": [
            "26933813",
            "28977399",
            "28444181"
      ],
      "ReferenceType": [
            "background",
            "background",
            "background"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [
            "April 27, 2021"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [
            "March 30, 2021"
      ],
      "ResultsFirstSubmitQCDate": [
            "March 30, 2021"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire measures duration of exercise-related activities (hours/week). The Duration variable can range from 0 - 399.75 hours per week. Higher scores indicate more activity.",
            "4-meter gait speed test measures the time (in seconds) taken to walk a distance of 4 meters. The total score has a range of 1 point - 4 points with the higher score indicating faster walk speed.",
            "Standard Physical Performance Battery (SPPB) Assessment has total score ranging from 0-4 with the higher score indicating better balance.",
            "Change in weight as measured in kilograms (kg).",
            "Hand grip strength as assessed by a dynamometer. Grip strength is recorded (in mmHg) three times for each hand. The average reading is reported for each hand.",
            "Multi-dimensional Fatigue Inventory (MFI) Questionnaire contains 20 questions with a 5-point scale. The MFI has total score ranging from 20-100 with the higher score indicating less fatigue.",
            "Investigating Choice Experiences for the Preferences of Older People (ICEpop) Capability measure for Older people (ICECAP) questionnaire has total score ranging from 5-20 with the higher score indicating greater quality of life.",
            "Short Form (SF)-36 Questionnaire has consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. Lower scores indicate the more disability, and higher scores indicate less disability.",
            "EuroQoL (EQ)- 5 Dimension (5D)- 3 levels (3L) Questionnaire has total score ranging from 0-10 for the 5 dimensions. Higher scores indicate better Quality of Life.",
            "EuroQoL - 5 Dimension - 3 levels (EQ-5D-3L) Overall health status question has a range of 0-100. Higher scores indicate better Quality of Life.",
            "University of Pennsylvania Smell Identification Test (UPSIT) smell test booklet has a total score ranging from 0-40 with higher scores indicating better olfaction.",
            "Any reported death from any cause.",
            "Change in dobutamine stress echocardiogram induced ejection fraction",
            "Change in inflammatory markers including C-Reactive Protein (CRP) and Fibrinogen serum samples as measured in mg/L.",
            "Change in inflammatory markers including Interleukin (IL)-6 and Tumor Necrosis Factor (TNF) Alpha from serum samples as measured in pg/mL.",
            "Change in inflammatory marker D-Dimer from serum samples as measured in mg/dL."
      ],
      "SecondaryOutcomeMeasure": [
            "Change in Frailty as Assessed by CHAMPS Questionnaire",
            "Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test",
            "Change in Slowing of Mobility as Measured by SPPB",
            "Change in Weight",
            "Change in Diminished Hand Grip Strength",
            "Change in Exhaustion as Measured by the MFI Questionnaire",
            "Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire",
            "Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire",
            "Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire",
            "Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale.",
            "Change in Sense of Smell as Measured by UPSIT",
            "Death",
            "Change in Ejection Fraction (EF)",
            "Change in Inflammatory Markers Levels",
            "Change in Inflammatory Markers",
            "Change in Inflammatory Marker D-dimer Levels"
      ],
      "SecondaryOutcomeTimeFrame": [
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "Up to 12 months.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit.",
            "At baseline and 6 month follow-up visit."
      ],
      "SeeAlsoLinkLabel": [
            "Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine"
      ],
      "SeeAlsoLinkURL": [
            "http://isci.med.miami.edu"
      ],
      "SeriousEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [
            "Vascular disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Cardiac disorders",
            "Blood and lymphatic system disorders",
            "Renal and urinary disorders"
      ],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG002",
            "EG003",
            "EG004",
            "EG005",
            "EG006",
            "EG000",
            "EG001",
            "EG002",
            "EG003",
            "EG004",
            "EG005",
            "EG006",
            "EG000",
            "EG001",
            "EG002",
            "EG003",
            "EG004",
            "EG005",
            "EG006",
            "EG000",
            "EG001",
            "EG002",
            "EG003",
            "EG004",
            "EG005",
            "EG006",
            "EG000",
            "EG001",
            "EG002",
            "EG003",
            "EG004",
            "EG005",
            "EG006"
      ],
      "SeriousEventStatsNumAffected": [
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0"
      ],
      "SeriousEventStatsNumAtRisk": [
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20",
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20",
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20",
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20",
            "5",
            "5",
            "5",
            "10",
            "10",
            "10",
            "20"
      ],
      "SeriousEventStatsNumEvents": [
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "1",
            "0",
            "0",
            "0",
            "0",
            "0"
      ],
      "SeriousEventTerm": [
            "Stroke",
            "Upper Respiratory Infection",
            "Congestive Heart Failure",
            "Leukocytosis",
            "Microscopic Hematuria"
      ],
      "StartDate": [
            "March 3, 2014"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "July 2021"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "February 17, 2014"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "February 14, 2014"
      ],
      "StudyFirstSubmitQCDate": [
            "February 14, 2014"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}